NYMC > The Holz Lab > Research

Research

Estrogen

Cuesta R, Gritsenko MA, Petyuk VA, Shukla AK, Tsai CF, Liu T, McDermott JE, and Holz MK. Phosphoproteome Analysis Reveals Estrogen-ER pathway as a modulator of mTOR activity via DEPTOR. Molecular & Cellular Proteomics 2019;18(8):1607-1618.

Cuesta R, Berman AY, Alayev A, and Holz MK. Estrogen receptor α promotes protein synthesis by fine-tuning the expression of the eukaryotic translation initiation factor 3 subunit f (eIF3f). J Biol Chem. 2019; 294(7):2267-2278.

Bostner J, Alayev A, Berman AY, Fornander T, Nordenskjöld B, Holz MK and Stål O. Raptor localization and estrogen-dependent breast cancer growth.  Breast Cancer Res and Treat. 2018; 168(1):17-27.

Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol, 2017; 1(35):1-9 doi:10.1038/s41698-017-0038-6

Berman AY, Manna S, Schwartz NS, Sun Y, Yu JJ, Behrmann CA, Plas DR, Alayev A, Holz MK. ERRα regulates the growth of triple-negative breast cancer cells via S6K1-dependent mechanism. Signal Transduct Target Ther. 2017;2. pii: e17035. doi: 10.1038/sigtrans.2017.35.

Li C, Liu Y, Zhang E, Sun Y, Li N, Medepalli K, Wikenheiser-Brokamp K, Plas DR, Sun J, Chen Y, Franz DN, Capal JK, Mays M, Kwiatkowski D, Alayev A, Holz MK, Kruger D, Siroky D and Yu JJ. Tuberin regulates prostaglandin E receptor 3-mediated viability of mTORC1-hyperactive cells via Rheb. Mol Cancer Res. 2017;15(10):1318-1330.

Alayev A, Salamon RS, Schwartz NS, Berman AY, Wiener SL, and Holz MK. Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer. J Cell Physiol. 2017; 232(2):436-446.

Alayev A, Salamon RS, Manna S, Schwartz NS, Berman AY, Holz MK. Estrogen induces RAD51C expression and localization to sites of DNA damage. Cell Cycle. 2016;15(23):3230-3239.

Cuesta R and Holz MK. RSK-mediated down-regulation of PDCD4 is required for the proliferation, survival, and migration in a model of triple-negative breast cancer. Oncotarget, 2016;7(19):27567-83. 

Klionsky DJ et al., Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy (3rd edition), Autophagy 2016;12(1):1-222.

Manna S. and Holz MK. Tamoxifen action in ER-negative breast cancer. Signal Transduction Insights 2016; 5, 1-

Alayev A, Salamon RS, Berger SM, Schwartz NS, Cuesta R, Snyder RB, Holz MK. mTORC1 directly phosphorylates and activates ERα upon estrogen stimulation. Oncogene. 2016; 35(27):3535-43

Manna S, Bostner J, Sun Y, Miller LD, Alayev A, Schwarz NS, Lager E, Fornander T, Nordenskjöld B, Yu JJ, Stål O, Holz MK. ERRa is a marker of tamoxifen response and survival in triple-negative breast cancer. Clin Cancer Res 2016; 22: 1421.

Alayev A, Berger SM and Holz MK. Resveratrol as a novel treatment for diseases with mTOR pathway hyperactivation. Ann. N.Y. Acad. Sci. 2015; 1348(1):116-23.

Alayev A, Salamon RS, Sun Y, Schwartz NS, Yu JJ, Holz MK. Effects of Combining Rapamycin and Resveratrol on Apoptosis and Growth of TSC2-Deficient Xenograft Tumors. Am. J. Respir. Cell Mol. Biol. 2015; 53(5), 637–646.

Pollack D, Xiao Y, Shrivastava V, Levy A, Andrusier M, D'Armiento JM, Holz MK, Vigodner M. CDK14 expression is down-regulated by cigarette smoke in vivo and in vitro. Toxicol. Lett. 2015; 234(2):120-30

Alayev A, Berger SM, Kramer MY, Schwartz NS, Holz MK. The combination of rapamycin and resveratrol blocks autophagy and induces apoptosis in breast cancer cells. J. Cell. Biochem. 2015; 116(3):450-7.

Alayev A, Doubleday PF, Berger SM, Ballif BA, Holz MK. Phosphoproteomics Reveals Resveratrol-

Dependent Inhibition of Akt/mTORC1/S6K1 Signaling. J. Proteome Res. 2014; 13(12):5734-42.

Alayev A, Sun Y, Snyder RB, Berger SM, Yu JJ, Holz MK. Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells. Cell Cycle. 2014; 13(3):371-82.

Alayev A. and Holz MK. mTOR Signaling for Biological Control and Cancer. J. Cell. Physiol., 2013; 228: 1658–1664.

Holz, MK. The role of S6K1 in ER-positive breast cancer. Cell Cycle, 2012; 11(17):3159-65.

Maruani DM, Spiegel TN, Harris EN, Shachter AS, Unger HA, Herrero-González S, Holz MK. Estrogenic regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation. Oncogene, 2012; 31(49):5073–5080.

Yamnik RL and Holz MK. mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation. FEBS Lett. 2010; 584(1):124-8.

Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ, Holz MK. S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem. 2009; 284(10):6361-9.

Holz MK and Blenis J. (2008) Ribosomal protein S6 kinase beta-1 target assessment review. Targeted Proteins Database, Current Biodata. doi:10.2970/tpdb.2008.212.

Holz MK and Blenis J. (2008)  Ribosomal protein S6 kinase beta-2 target assessment review.  Targeted Proteins Database, Current Biodata. doi:10.2970/tpdb.2008.161.

Holz MK and Blenis J. (2008)  Eukaryotic translation initiation factor 4E-binding protein 1 target assessment review. Targeted Proteins Database, Current Biodata. doi:10.2970/tpdb.2008.208.

Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J, Sonenberg N, Blenis J. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem. 2007; 282(19):14056-64.

Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell. 2005; 123(4):569-80.

Holz MK and Blenis J. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem. 2005; 280(28):26089-93.